Celcuity/$CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Ticker
$CELC
Sector
Primary listing
Employees
155
Headquarters
Website
Celcuity Metrics
BasicAdvanced
$5.9bn
-
-$3.79
0.41
-
Price and volume
Market cap
$5.9bn
Beta
0.41
52-week high
$129.09
52-week low
$9.51
Average daily volume
792k
Financial strength
Current ratio
10.547
Quick ratio
9.999
Long term debt to equity
320.075
Total debt to equity
320.128
Interest coverage (TTM)
-10.04%
Profitability
EBITDA (TTM)
-172.035
Management effectiveness
Return on assets (TTM)
-30.24%
Return on equity (TTM)
-163.80%
Valuation
Price to book
63.41
Price to tangible book (TTM)
58.28
Price to free cash flow (TTM)
-36.957
Free cash flow yield (TTM)
-2.71%
Free cash flow per share (TTM)
-3.284
Growth
Earnings per share change (TTM)
33.63%
3-year earnings per share growth (CAGR)
12.83%
10-year earnings per share growth (CAGR)
81.66%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $5.9B as of May 01, 2026.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of May 01, 2026.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.